• Scientific Breakthroughs in
    PET Imaging Agents

    Through innovations and developments in molecular imaging agents, FluoroPharma’s goal is to become the leader in early detection of coronary artery & alzheimer diseases

  • PET Scan Imaging Agents

    • Agent: Muscle State Imaging Agent
    • Type: Fatty Acid (Labeled with Fluorine 18)
    • Condition: Coronary Artery Disease
    • Status: Phase 1 clinical trials completed
    CardioPET

    This imaging agent exploits the dietary needs of the heart as it relates to glucose and fatty acids. By introducing a chemical group that alters the breakdown of the hydro carbons (fatty acids) we can clearly see the anatomic location and the state of the muscle within specific arteries and detect problems in advance of symptoms that would lead to a stress test.

    • image description
    • image description
    • image description
    • image description
    • image description
    • image description

  • PET Scan Imaging Agents

    • Agent: Blood Flow Imaging Agent
    • Type: Positively Charged Molecule (Labeled with Fluorine 18)
    • Condition: Coronary Artery Disease
    • Status: Phase 1 clinical trials completed
    BFPET

    By changing the polarity of the cell walls this imaging agent allows a view into the blood flow of specific arteries. This view identified tissues with perfusions and mitochondrial integrity as well indentifies the state of the tissue.

    • image description
    • image description
    • image description
    • image description
    • image description
    • image description

  • PET Scan Imaging Agents

    • Agent: Vulnerable plaque Imaging Agent
    • Type: Receptor Connecting Molecule (Labeled with Fluorine 18)
    • Condition: Coronary Artery Disease
    • Status: Pre Clinical studies Completed
    VasoPET

    By targeting the active adenosine phosphate molecule receptors which are associated with inflammatory conditions this imaging agent allows us to visualize potential areas that may cause embolisms and thrombosis.

    • image description
    • image description
    • image description
    • image description

  • PET Scan Imaging Agents

    • Agent: Amyloid Deposit Imaging Agent
    • Type: Molecule that targets that bind Amyloid Protein (Labeled with Fluorine 18)
    • Condition: Alzheimer’s Disease
    • Status: Development Stage
    AZPET

    This Imaging agent attaches to the amyloid deposits (plaque) in the brain and makes them visible on a PET Scan thus allowing the early detection of Alzheimer’s disease

    • image description
    • image description
    • image description
    • image description

Shaping the Future of Molecular PET Imaging

FluoroPharma (FPMI) is developing breakthrough molecular imaging agents for positron emission tomography (PET) which will fulfill critical unmet medical needs. The company’s agents will give clinicians important tools for the detection and assessment of pathology before clinical manifestation of diseases.

Company News

FluoroPharma to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference Jan 13 2012, 10:54 AM EST
FluoroPharma Announces Addition to the Board of Directors Dec 30 2011, 9:46 AM EST
FluoroPharma Announces Aggregate of $7M Capital Raise in 2011 Dec 20 2011, 8:02 AM EST

CardioPET

image description

This imaging agent exploits the dietary needs of the heart as it relates to glucose and fatty acids. By introducing a chemical group which alters the breakdown of fatty acids (the hearts main food source) we can track their distribution into the heart muscle and asses it's health and viability.

BFPET

image description

By recognizing the electrical charge of the myocardial cell walls this imaging agent allows a view into the blood flow of the heart. It identifies tissue with perfusion as well as mitochondrial integrity of the cells - a strong indicator for cell viability.

VasoPET

image description

By targeting active molecule receptors associated with inflammatory conditions this imaging agent allows us to visualize areas in the blood vessels that may potentially initiate thrombosis and embolism.

AZPET

image description

This imaging agent specifically seeks out and attaches to amyloid deposits in the brain. The following PET scan reveals the areas where amyloid plaque has deposited and allows for the early detection of Alzheimer’s disease.